Actemra Approved for Rheumatoid Arthritis

MONDAY, Jan. 11 (HealthDay News) -- Actemra (tocilizumab) has been approved by the U.S. Food and Drug Administration to treat rheumatoid arthritis among people who haven't responded to, or who cannot tolerate, other approved RA drugs, the agency said Monday.

Actemra was approved for limited use because of adverse reactions noted in clinical trials, including the possibility of elevated liver enzymes, elevated "bad" cholesterol (LDL), hypertension, and gastrointestinal perforations, the agency said in a news release.

Actemra blocks an immune system protein called interleukin-6, which is found in excess in people with rheumatoid arthritis.

As a condition of the approval, San Francisco-based Genentech, the drug's marketer, must conduct additional clinical studies to evaluate the drug's long-term effectiveness and cardiovascular safety, the FDA said.

The agency said it also is requiring development of a Risk Evaluation and Mitigation Strategy for doctors, to inform physicians on how to monitor patients for possible liver or gastrointestinal side effects.

The most common adverse effects found in clinical testing included upper respiratory infections and other "serious" infections, headache, nasal and sinus inflammation, high blood pressure and increased liver enzymes, the agency said.

More information

The FDA has more about this approval.

-- This embed didnt make it to copy for story id = 9534391.
Join the Discussion
blog comments powered by Disqus
 
You Might Also Like...
See It, Share It
United States Carli Lloyd celebrates with teammates Ali Krieger and Morgan Brian after scoring on a penalty kick against Germany during the second half of a semifinal in the Womens World Cup finals, Tuesday, June 30, 2015, in Montreal, Canada.
Ryan Remiorz/The Canadian Press via AP
PHOTO:
Elaine Thompson/AP Photo
PHOTO: In this image released by Lionsgate, Theo James, from left, Shailene Woodley and Miles Teller appear in a scene from The Divergent Series: Insurgent.
Andrew Cooper/Lionsgate/AP Photo